Short answer
Absci Corp (ABSI) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $378,000 (down 77.8% year over year) with net income of −$29M.
Q3 2025 key financials · XBRL
- Revenue
- $378,000
- −77.8% YoY · −36.3% QoQ
- Net income
- −$29M
- −4.8% YoY · +6.1% QoQ
- Operating margin
- -7977.2%
- EPS (diluted)
- −$0.20
- +16.7% YoY · +16.7% QoQ
Source: XBRL data from the Absci Corp (ABSI) Q3 2025 10-Q on SEC EDGAR. USD.
Absci Corp Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0.4M, down 78% YoY from $1.7M, driven by milestone timing and program mix
- Operating loss $30.2M vs $28.9M YoY; operating margin -7,975% vs -1,699% YoY
- R&D expense $19.2M, up 7% YoY; SG&A $8.4M, down 9% YoY
- Cash, equivalents, and marketable securities $152.5M; $35.7M net ATM proceeds during nine months
- Cash expected sufficient for at least 12 months; future funding needs tied to clinical development and partnerships
Risk Factors
- No newly added risk identified; filing incorporates the December 31, 2024 Form 10-K risk factors
- Regulatory risk: reported FDA staffing cuts may delay IND reviews, regulations, guidance, or enforcement
- Operational risk: no partner has licensed related intellectual property for clinical or commercial use as of October 31, 2025
- Financial risk: $152.5 million in cash, equivalents, and marketable securities expected to fund operations for at least 12 months
- Development risk: ABS-101 Phase 1 results showed extended half-life versus first-generation competitors but not next-generation programs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Absci Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.